Skip to main content
Jommel Macaraeg on Muck Rack

Jommel Macaraeg

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jommel

Contact Jommel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma - Leukemia

|
By Tadeusz Kubicki, Anna E. Pula, Angela Jones, Alexander Bick, Michael Savona, Andrzej J. Jakubowiak, Benjamin A. Derman, Kathryn Shimamoto, Jommel Macaraeg
| Nature Verified
To The Editor: Multiple myeloma (MM) accounts for 10% of all blood cancers [1]. Standard of care treatment with autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance improved survival, but MM remains incurable [1]. A diverse therapeutic armamentarium has changed MM into a relapsing-remitting cancer. However, as patients live several years, there has been a steady increase in the frequency of second primary hematologic malignancies (SPHM).
Open in Who Shared Issue with article?
See all 1 articles